Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Lisata Therapeutics (LSTA) Leases (2016 - 2025)

Lisata Therapeutics filings provide 8 years of Leases readings, the most recent being $47000.0 for Q2 2025.

  • For the quarter ending Q2 2025, Leases fell 79.11% year-over-year to $47000.0, compared with a TTM value of $47000.0 through Jun 2025, down 79.11%, and an annual FY2024 reading of $138000.0, down 55.19% over the prior year.
  • Leases hit $47000.0 in Q2 2025 for Lisata Therapeutics, down from $93000.0 in the prior quarter.
  • The five-year high for Leases was $425000.0 in Q1 2023, with the low at $47000.0 in Q2 2025.
  • Median Leases over the past 3 years was $246000.0 (2024), compared with a mean of $242000.0.
  • The sharpest move saw Leases plummeted 37.18% in 2024, then plummeted 79.11% in 2025.
  • Year by year, Leases stood at $308000.0 in 2023, then tumbled by 55.19% to $138000.0 in 2024, then crashed by 65.94% to $47000.0 in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $47000.0, $93000.0, and $138000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.